See more : Dongfeng Motor Group Company Limited (0489.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Amicus Therapeutics, Inc. (FOLD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amicus Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- S.P. Apparels Limited (SPAL.NS) Income Statement Analysis – Financial Results
- PFA Invest Balance B (PFIBAB.CO) Income Statement Analysis – Financial Results
- Professional Diversity Network, Inc. (IPDN) Income Statement Analysis – Financial Results
- Nexa Resources S.A. (NEXA) Income Statement Analysis – Financial Results
- Chill Brands Group PLC (CHLL.L) Income Statement Analysis – Financial Results
Amicus Therapeutics, Inc. (FOLD)
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0.00 | 1.22M | 363.00K | 18.41M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M | 14.40M | 6.24M | 833.00K | 1.83M | 0.00 | 13.49M | 20.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M | 76.84M | 30.69M | 4.13M | -1.83M | 1.22M | -13.13M | -1.97M | 21.43M | 922.00K | 64.36M | 14.97M | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.65% | 88.28% | 88.72% | 88.10% | 87.95% | 84.21% | 83.11% | 83.20% | 0.00% | 100.00% | -3,616.80% | -10.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M | 270.90M | 149.31M | 104.79M | 76.94M | 47.62M | 41.94M | 50.27M | 50.86M | 39.04M | 48.08M | 37.76M | 31.07M | 33.63M | 13.65M | 0.00 | 4.43M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.20M | 0.00 | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M | 127.20M | 88.67M | 71.15M | 47.27M | 20.72M | 18.89M | 19.36M | 19.88M | 15.66M | 19.97M | 19.67M | 15.28M | 12.28M | 6.88M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.34M | 6.21M | 8.85M | 4.78M | -5.63M | 6.01M | -4.79M | -80.00K | -77.00K | 1.72M | 21.00K | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 0.00 | 0.00 | -8.81M | 0.00 |
| Operating Expenses | 427.65M | 495.06M | 470.97M | 473.70M | 461.01M | 402.32M | 241.57M | 179.19M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Cost & Expenses | 472.85M | 533.66M | 505.43M | 504.74M | 482.98M | 416.72M | 247.81M | 180.02M | 126.05M | 69.89M | 62.56M | 71.34M | 72.32M | 56.76M | 70.19M | 58.92M | 47.59M | 46.86M | 20.83M | -8.81M | 6.60M |
| Interest Income | 7.08M | 3.02M | 509.00K | 3.23M | 10.25M | 10.46M | 4.10M | 1.60M | 929.00K | 223.00K | 174.00K | 316.00K | 160.00K | 156.00K | 997.00K | 4.82M | 0.00 | 1.99M | 609.52K | 0.00 | 5.00K |
| Interest Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M | 22.40M | 17.24M | 5.40M | 1.58M | 1.48M | 46.00K | 89.00K | 148.00K | 260.00K | 278.00K | 218.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952.45K | 667.38K | 0.00 | 132.00K |
| EBITDA | -92.08M | -199.58M | -202.87M | -242.98M | -332.26M | -322.47M | -428.29M | -195.14M | -128.71M | -67.01M | -61.38M | -50.24M | -46.54M | -53.76M | -4.16M | -37.64M | -44.57M | -44.70M | -20.20M | -8.81M | -6.47M |
| EBITDA Ratio | -23.06% | -58.28% | -64.19% | -89.14% | -180.52% | -346.79% | -533.94% | -3,529.85% | 0.00% | -5,471.49% | -16,611.57% | -276.41% | -229.27% | -5,816.05% | -4.19% | -283.71% | -2,489.85% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M | -328.78M | -441.99M | -181.89M | -130.44M | -68.70M | -64.18M | -52.93M | -50.89M | -55.84M | -7.35M | -43.96M | -45.81M | -46.86M | -20.83M | -8.81M | -6.60M |
| Operating Income Ratio | -18.40% | -62.09% | -65.44% | -93.47% | -165.03% | -360.32% | -1,196.82% | -3,668.62% | 0.00% | -5,612.83% | -17,680.72% | -287.50% | -237.41% | -6,056.18% | -11.42% | -293.69% | -2,567.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.61M | -37.61M | -41.63M | -30.40M | -55.17M | -23.61M | -7.14M | -21.89M | -6.07M | -1.34M | 1.04M | 901.00K | 2.85M | -237.00K | 783.00K | 4.60M | 4.64M | 514.36K | 247.27K | 0.00 | -168.00K |
| Income Before Tax | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M | -349.09M | -449.12M | -203.78M | -132.12M | -70.04M | -63.15M | -52.03M | -48.04M | -56.08M | -6.57M | -39.36M | -41.17M | -46.34M | -20.58M | 0.00 | -6.77M |
| Income Before Tax Ratio | -37.59% | -73.52% | -79.06% | -105.12% | -195.30% | -382.58% | -1,216.14% | -4,110.15% | 0.00% | -5,722.14% | -17,395.32% | -282.60% | -224.13% | -6,081.89% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.48M | -5.47M | 8.91M | 2.60M | 478.00K | -94.00K | -165.12M | -3.74M | 1.50M | -1.11M | -3.51M | -3.25M | -3.63M | -1.14M | 278.00K | 0.00 | 351.00K | -514.36K | -611.80K | 8.81M | 0.00 |
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.34M | -19.97M | -8.81M | -6.77M |
| Net Income Ratio | -37.96% | -71.85% | -81.98% | -106.12% | -195.56% | -382.48% | -769.03% | -4,034.73% | 0.00% | -5,631.21% | -16,427.82% | -264.98% | -207.20% | -5,958.35% | -10.20% | -262.95% | -2,307.57% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| EPS Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 | -1.16 | -1.07 | -1.28 | -1.98 | -0.29 | -1.75 | -3.11 | -62.97 | -48.69 | -28.64 | -22.01 |
| Weighted Avg Shares Out | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
| Weighted Avg Shares Out (Dil) | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M | 185.79M | 153.36M | 134.40M | 109.92M | 74.44M | 51.29M | 45.57M | 34.57M | 27.73M | 22.62M | 22.49M | 13.24M | 735.97K | 410.22K | 307.54K | 307.54K |
US FDA approves Amicus Therapeutics' muscle disorder treatment
Amicus Therapeutics said on Thursday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a muscle disorder called Pompe disease.
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept.
3 Stocks Worth a Watch for Solid Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).
Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual...
Amicus Therapeutics: U.K. Approval Expands Global Reach
Amicus Therapeutics is a biotech company focused on rare metabolic diseases, showing positive growth in revenue and decreasing operating expenses. The company's product portfolio includes treatments for Fabry disease, Pompe disease, and Batten disease, with potential gene therapies in development....
WuXi Biologics Reports Solid 2023 Interim Results
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth, Strong Momentum Continued Non-COVID Late-phase And Commercial Manufacturing Revenue Grew by 130.3% Y-o-Y "R" in CRDMO Accelerated...
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Pombiliti ® (cipaglucosidase alfa) + Opfolda ® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain
Source: https://incomestatements.info
Category: Stock Reports